Since they highlighted a diminution of DC-10 in patients’ blood exhibiting autoimmunity (in Type 1 diabetes and Multiple sclerosis models) or severe inflammation (in Celiac disease model), DC-10 could be defined as biomarker of tolerance and used in clinical applications (12). This evidence concerns the gene FBXO8 and Autoimmunity.